<DOC>
	<DOC>NCT00038909</DOC>
	<brief_summary>To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing laboratories (one in Europe and one in North America).</brief_summary>
	<brief_title>Study Evaluating ReFacto in Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients who were or are enrolled in Study CTN 93R8330XX/C974128, and have been treated with ReFacto® during this study are eligible for participation. The patient (or legal guardian) must be willing to give written informed consent before any studyrelated procedures are performed. A blood sample will be collected from each patient for the purpose of this study and will be analyzed at one or both of the designated central laboratories. Any condition which, in the investigator's opinion, places the patient at undue risk.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>